T1	Participants 69 101	patients with myasthenia gravis.
T2	Participants 111 194	Patients with myasthenia gravis receive pyridostigmine, an anticholinesterase agent
T3	Participants 537 594	patients with myasthenia gravis on pyridostigmine therapy
